First Time Loading...

Addex Therapeutics Ltd
SIX:ADXN

Watchlist Manager
Addex Therapeutics Ltd Logo
Addex Therapeutics Ltd
SIX:ADXN
Watchlist
Price: 0.0956 CHF -1.65%
Updated: Mar 29, 2024

Intrinsic Value

ADXN doesn't have a meaningful market cap.

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. [ Read More ]

The intrinsic value of one ADXN stock under the Base Case scenario is 0.3662 CHF. Compared to the current market price of 0.0956 CHF, Addex Therapeutics Ltd is Undervalued by 74%.

Key Points:
ADXN Intrinsic Value
Base Case
0.3662 CHF
Undervaluation 74%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Addex Therapeutics Ltd

Backtest ADXN Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ADXN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Addex Therapeutics Ltd

Current Assets 5.7m
Cash & Short-Term Investments 4.8m
Receivables 373.4k
Other Current Assets 615.2k
Non-Current Assets 395.4k
PP&E 341.1k
Other Non-Current Assets 54.3k
Current Liabilities 1.9m
Accounts Payable 389.8k
Accrued Liabilities 1.3m
Other Current Liabilities 206.4k
Non-Current Liabilities 262.7k
Long-Term Debt 116.9k
Other Non-Current Liabilities 145.8k
Efficiency

Earnings Waterfall
Addex Therapeutics Ltd

Revenue
2.5m CHF
Operating Expenses
-16.8m CHF
Operating Income
-14.4m CHF
Other Expenses
-1.1m CHF
Net Income
-15.5m CHF

Free Cash Flow Analysis
Addex Therapeutics Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ADXN Profitability Score
Profitability Due Diligence

Addex Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional ROIC
ROIC is Increasing
Positive 1-Year Revenue Growth
27/100
Profitability
Score

Addex Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

ADXN Solvency Score
Solvency Due Diligence

Addex Therapeutics Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
50/100
Solvency
Score

Addex Therapeutics Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ADXN Price Targets Summary
Addex Therapeutics Ltd

Wall Street analysts forecast ADXN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADXN is 0.1632 CHF with a low forecast of 0.1616 CHF and a high forecast of 0.168 CHF.

Lowest
Price Target
0.1616 CHF
69% Upside
Average
Price Target
0.1632 CHF
71% Upside
Highest
Price Target
0.168 CHF
76% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

ADXN Price
Addex Therapeutics Ltd

1M 1M
+53%
6M 6M
+45%
1Y 1Y
-49%
3Y 3Y
-94%
5Y 5Y
-94%
10Y 10Y
-95%
Annual Price Range
0.0956
52w Low
0.04
52w High
0.188
Price Metrics
Average Annual Return -30.25%
Standard Deviation of Annual Returns 48.17%
Max Drawdown -98%
Shares Statistics
Market Capitalization 12.8m CHF
Shares Outstanding 134 374 000
Percentage of Shares Shorted
N/A

ADXN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Addex Therapeutics Ltd Logo
Addex Therapeutics Ltd

Country

Switzerland

Industry

Biotechnology

Market Cap

12.8m CHF

Dividend Yield

0%

Description

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 28 full-time employees. The company went IPO on 2007-05-22. The firm focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. The company also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Contact

GENEVE
Plan-les-Ouates
Chemin des Mines, 9
+41228841555.0
https://www.addextherapeutics.com/

IPO

2007-05-22

Employees

28

Officers

Co-Founder, CEO & Director
Mr. Timothy Mark Dyer
Chief Medical Officer & Director
Dr. Roger G. Mills M.D.
Head of Finance
Mr. Lénaic Teyssédou
Head of Discovery - Chemistry
Dr. Jean-Philippe Rocher Ph.D.
Head of Discovery - Biology
Dr. Robert Lutjens
Head of Translational Science
Dr. Mikhail Kalinichev Ph.D.

See Also

Discover More
What is the Intrinsic Value of one ADXN stock?

The intrinsic value of one ADXN stock under the Base Case scenario is 0.3662 CHF.

Is ADXN stock undervalued or overvalued?

Compared to the current market price of 0.0956 CHF, Addex Therapeutics Ltd is Undervalued by 74%.